Abstracts tagged "clinical trials"

Abstract Number: 1909 • 2017 ACR/ARHP Annual Meeting
Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study
Mark C. Genovese¹, Arthur Kavanaugh², Kevin Winthrop³, Maria Greenwald⁴, Lucia Ponce⁵, Favio Enriquez Sosa⁶, Mykola Stanislavchuk⁷, Minodora Mazur⁸, Alberto Spindler⁹, Regina Cseuz¹⁰, Natalya Nikulenkova¹¹, Maria Glowacka-Kulesz¹², Istvan Szombati¹³, Anna Dudek¹⁴, Neelufar Mozaffarian¹⁵, Joy Greer¹⁵, Xiao Ding¹⁵, Pille Harrison¹⁶, Annegret Van der Aa¹⁶, René Westhovens¹⁷ and Rieke Alten¹⁸, ¹Stanford University Medical Center, Palo Alto, CA, ²Medicine, University of California, San Diego, La Jolla, CA, ³Oregon Health Sciences University, Portland, OR, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Consulta Privada Dra. Lucia Ponce, Temuco, Chile, ⁶Clinstile SA de CV, Col., Mexico City, Mexico, ⁷Vinnitsa Regional Clinical Hospital, Vinnitsa, Ukraine, ⁸IMSP Inst. de Cardiologie, Chisinau, Moldova, The Republic of, ⁹Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ¹⁰Revita Reumatologiai Rendelo, Budapest, Hungary, ¹¹Vladimir Reg Clin Hosp, Vladimir, Russian Federation, ¹²Silesiana Centrum Medyczne, Wroclawska, Poland, ¹³QUALICLINIC Kft., Budapest, Hungary, ¹⁴Centrum Medyczne AMED Warszawa Targówek, Warszawa, Poland, ¹⁵Gilead Sciences, Inc, Foster City, CA, ¹⁶Galapagos NV, Mechelen, Belgium, ¹⁷KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ¹⁸Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib is an orally administered, selective inhibitor of Janus Kinase 1 (JAK1) currently in Phase 3 development for the treatment of rheumatoid arthritis (RA).…
Abstract Number: 535 • 2017 ACR/ARHP Annual Meeting
Effect of a Step-up or Step-Down in Tofacitinib Dose on Efficacy and Safety in Long-Term Extension Studies
Ruediger Mueller¹, Hendrik Schulze-Koops², Daniel E Furst³, Stanley B Cohen⁴, Kenneth Kwok⁵, Anna Maniccia⁵, Lisy Wang⁶, Ermeg Akylbekova⁷ and Johannes von Kempis¹, ¹Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Klinikum der Universität München, Munich, Germany, ³UCLA, Los Angeles, CA, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT, ⁷QuintilesIMS, Durham, NC
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Efficacy and safety of tofacitinib 5 and 10 mg BID have been…
Abstract Number: 2074 • 2017 ACR/ARHP Annual Meeting
A Series of Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Studies to Evaluate the Efficacy, Safety, and Dose-Response Relationship of Orally Administered URC102, a Novel URAT1 Inhibitor, in Korean Patients with Gout
Jae-Bum Jun¹, Howard Lee², Chang-Hee Suh³, Chang Keun Lee⁴, Dong Wook Kim⁵, Jung-Yoon Choe⁶, Sang-Heon Lee⁷, Sang-Hyon Kim⁸, Seung-Jae Hong⁹, So-Young Bang¹⁰, Sung Jae Choi¹¹, Yong-Beom Park¹², Makoto Onohara¹³, Jeongeun Choi¹⁴, Jung Soo Song¹⁵ and Won Park¹⁶, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of (South), ³Ajou University School of Medicine, Suwon, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Inje University College of Medicine, Busan, Korea, Republic of (South), ⁶Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ⁷Division of Rheumatology, Department of Internal Medicine,, Konkuk University School of Medicine, Seoul, Korea, Republic of (South), ⁸Division of Rheumatology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea, Daegu, Korea, Republic of (South), ⁹Department of Rheumatology, Kyung Hee University Medical Center, Seoul, Korea, Republic of (South), ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ¹¹Internal Medicine, Korea University Medical Center, Seoul, Korea, Republic of (South), ¹²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ¹³Science and Strategy, Translational Clinical Research, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan, ¹⁴JW Pharmaceutical Corporation, Seoul, Korea, Republic of (South), ¹⁵Rheumatology, Chung-Ang University College of Medicine, Seoul, Korea, Republic of (South), ¹⁶Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South)
Background/Purpose: URC102 is a novel URAT1 inhibitor under clinical development for the treatment of hyperuricemia with gout. A series of double-blind, placebo-controlled, randomized, multicenter, phase…
Abstract Number: 41 • 2017 Pediatric Rheumatology Symposium
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine Brunner¹, Nicola Ruperto², Alberto Martini², Athimalaipet Ramanan³, Rubén Cuttica⁴, Jennifer E. Weiss⁵, Michael Henrickson⁶, Heinrike Schmeling⁷, Jordi Anton⁸, Kirsten Minden⁹, Joy Hsu¹⁰, Kamal Bharucha¹¹, Sunethra Wimalasundera¹², Alysha K. Kadva¹³, Ruchi Upmanyu¹², Navita L. Mallalieu¹⁰, Daniel Lovell⁶ and Fabrizio De Benedetti¹⁴, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO Coordinating Centre, Genoa, Italy, ³Bristol Royal Hospital for Children, Bristol, United Kingdom, ⁴Hospital Gral de Niños Pedro Elizalde, Buenos Aires, Argentina, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁷University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁸Hospital Sant Joan de Deu, Barcelona, Spain, ⁹Charité – University of Medicine Berlin, Berlin, Germany, ¹⁰Roche Innovation Center, New York, NY, ¹¹Genentech, South San Francisco, CA, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom, ¹³Genentech, San Francisco, CA, ¹⁴IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: The efficacy and safety of intravenous (IV) tocilizumab (TCZ), an interleukin-6 receptor-alpha inhibitor, have been demonstrated in patients (pts) with polyarticular-course juvenile idiopathic…
Abstract Number: 5L • 2016 ACR/ARHP Annual Meeting
Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study
Mary Anne Dooley¹, William Pendergraft III², Ellen M. Ginzler³, Nancy J. Olsen⁴, James Tumlin⁵, Brad H. Rovin⁶, Frédéric A. Houssiau⁷, David Wofsy⁸, David A. Isenberg⁹, Neil Solomons¹⁰, Robert Huizinga¹¹ and AURA Study Group, ¹Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²Kidney Center, University of North Carolina, Chapel Hill, NC, ³Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ⁴Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA, ⁵Nephrology, University of Tennessee College of Medicine, Chattanooga, TN, ⁶Ohio State University Medical Center, Columbus, OH, ⁷Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ⁸Rheumatology, University of California, San Francisco, San Francisco, CA, ⁹Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ¹⁰Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ¹¹Clinical Affairs, Aurinia Pharmaceuticals Inc., Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel CNI intended for use in the treatment of autoimmune diseases such as lupus nephritis. VCS’s unique structure allows for…
Abstract Number: 6L • 2016 ACR/ARHP Annual Meeting
Myeloablative Autologous Transplantation of CD34+ -Selected Hematopoietic Stem Cells (HSCT) Vs Monthly Intravenous Cyclophosphamide (CYC) for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial
Keith Sullivan¹, Lynette Keyes-Elstein², Peter McSweeney³, Ashley Pinckney², Beverly Welch⁴, Maureen D Mayes⁵, Richard Nash³, Leslie J. Crofford⁶, Sharon Castina², Linda Griffith⁷, Ellen Goldmuntz⁸ and Daniel E. Furst⁹, ¹Duke University, Durham, NC, ²Rho, Inc, Chapel Hill, NC, ³Colorado Blood Cancer Institute, Denver, CO, ⁴6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁵Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ⁶Medicine, Vanderbilt University Medical Center, Nasville, TN, ⁷NIAID, NIH, Bethesda, MD, ⁸NIAID, National Institutes of Health, Bethesda, MD, ⁹David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Therapeutic options for diffuse cutaneous systemic sclerosis (dcSSc) are limited. The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial was a multicenter study designed to…
Abstract Number: 7L • 2016 ACR/ARHP Annual Meeting
Overall Reduction in Acute Flares during Treatment with Febuxostat Compared with Placebo over 2 Years in Patients with Early Gout
Nicola Dalbeth¹, Kenneth G. Saag², William Palmer³, Hyon K. Choi³, Barbara Hunt⁴, Patricia MacDonald⁴, Ulrich Thienel⁵ and Lhanoo Gunawardhana⁴, ¹University of Auckland, Auckland, New Zealand, ²University of Alabama at Birmingham, Birmingham, AL, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴Takeda Pharmaceuticals International, Deerfield, IL, ⁵RRD International, Rockville, MD

Background/Purpose: No clinical trials have previously investigated the frequency of acute flares in early gout or the benefit of instituting urate-lowering therapy (ULT) earlier in…
Abstract Number: 643 • 2016 ACR/ARHP Annual Meeting
Exposure-Response Analyses of Efficacy of ABT-122, a Dual-Variable Domain Immunoglobulin (DVD-Ig™) Targeting TNF-α and IL-17A, Compared with Adalimumab in Subjects with Rheumatoid Arthritis and Background MTX
Amit Khatri¹, Ben Klunder², Mukul Minocha³, Heikki T. Mansikka¹ and Ahmed A. Othman¹, ¹AbbVie Inc., North Chicago, IL, ²AbbVie, Ludwigshafen am Rhein, Germany, ³Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Both cytokines are expressed at increased…
Abstract Number: 1709 • 2016 ACR/ARHP Annual Meeting
Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept (Enbrel) in Patients with Psoriasis and Psoriatic Arthritis
Alan J. Kivitz¹, Kim Papp², Alim Devani³, Andreas Pinter⁴, Rodney Sinclair^5,6,7, Michael Ziv⁸, John Caminis⁹, Cass Kelleher¹⁰, Helen Tang¹¹, Barbara Finck¹⁰ and RaPsOdy study group , ¹Altoona Center for Clinical Research, Duncansville, PA, ²K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, ³Institute for Skin Advancement, Surgical and Cosmetic Dermatology, Calgary, AB, Canada, ⁴Dept. of Dermatology, Venereology and Allergology, Theodor-Stern-Kai 7, Frankfurt, Germany, ⁵University of Melbourne, E. Melbourne, Australia, ⁶Epworth Healthcare, E. Melbourne, Australia, ⁷Sinclair Dermatology Investigational Research, Education and Clinical Trials, E. Melbourne, Australia, ⁸Dept of Dermatology, Emek Medical Center, Afula, Israel, ⁹Shire, cambridge, MA, ¹⁰Clinical Science, Coherus BioSciences, Redwood City, CA, ¹¹Coherus BioSciences, Redwood City, CA
Background/Purpose: CHS-0214 is a proposed biosimilar of etanercept, a fusion protein inhibiting tumor necrosis factor. This Phase III multi-center study compared the efficacy and safety…
Abstract Number: 649 • 2016 ACR/ARHP Annual Meeting
Clinical Evaluation Usefulness of Standardized Protocol Strategies of Dose Reduction in Patients with Rheumatoid Arthritis in Clinical Remission Treated with Biologic Therapies. the Optibio Study
Carmen Bejerano¹, Natividad Oreiro¹, Carlos Fernandez-Lopez², Jose A Pinto-Tasende¹, Antonio Atanes¹, Bruno De Aspe¹, Genaro Graña Gil¹, Mercedes Freire¹, Manuel Acasuso³, Sonia Pertega⁴, Francisco J. de Toro¹ and Francisco J Blanco¹, ¹Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ²Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain, ³Centro de Salud San Jose, XAP Coruna, A Coruna, Spain, ⁴Epidemiology Unit, INIBIC - Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
Background/Purpose: The OPTIBIO study is a clinical trial whose primary endpoint is to evaluate the proportion of patients that after one year are maintained in…
Abstract Number: 2012 • 2016 ACR/ARHP Annual Meeting
Utility of the Lupus Low Disease Activity State Definition in Discriminating Responders in the Phase IIb Muse Trial of Anifrolumab in Systemic Lupus Erythematosus
E. Morand¹, A. Berglind², T. Sheytanova², R. Tummala³ and G. Illei³, ¹Monash University, Melbourne, Australia, ²AstraZeneca, Mölndal, Sweden, ³MedImmune, Gaithersburg, MD
Background/Purpose: Preliminary validation of a Lupus Low Disease Activity State (LLDAS) definition has demonstrated that LLDAS attainment is associated with reduced damage accrual in patients…
Abstract Number: 650 • 2016 ACR/ARHP Annual Meeting
ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain (DVD)–Ig™ in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Mark C. Genovese¹, Michael Weinblatt², Jacob A Aelion³, Heikki T. Mansikka⁴, Paul M. Peloso⁴, Kun Chen⁴, Yihan Li⁴, Ahmed A. Othman⁴, Amit Khatri⁴, Nasser S. Khan⁴ and Robert J. Padley⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Brigham and Women’s Hospital, Boston, MA, ³West Tennessee Research Institute, Jackson, TN, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Tumor necrosis factor (TNF) and interleukin 17 (IL-17) appear to independently contribute to the pathophysiology of rheumatoid arthritis (RA), synergistically inducing inflammatory mediators leading…
Abstract Number: 2222 • 2016 ACR/ARHP Annual Meeting
Tai Chi Is More Effective Than Aerobic Exercise in Treating Fibromyalgia: A Randomized Controlled Trial
Chenchen Wang¹, Christopher Schmid², Roger A. Fielding³, William F. Harvey¹, Lori Lyn Price⁴, Jeffrey B. Driban¹, Kieran Reid³, Robert A. Kalish⁵, Ramel Rones⁶ and Timothy E. McAlindon⁷, ¹Rheumatology, Tufts Medical Center, Boston, MA, ²Brown University School of Public Health, Providence, RI, ³Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, ⁴Clinical Care Research, Tufts Medical Center, Boston, MA, ⁵Div of Rheumatology, Tufts Medical Center, Boston, MA, ⁶Center for Mind–Body Therapies, Boston, MA, ⁷Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Fibromyalgia is a complex disorder with strong psychological and pain components and is best managed with multidisciplinary therapies. Previous studies have suggested that Tai…
Abstract Number: 911 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
John H. Stone¹, Katie Tuckwell², Sophie Dimonaco², Micki Klearman³, Martin Aringer⁴, Daniel Blockmans⁵, Elisabeth Brouwer⁶, Maria C. Cid⁷, Bhaskar Dasgupta⁸, Juergen Rech⁹, Carlo Salvarani¹⁰, Robert F. Spiera¹¹, Sebastian H. Unizony¹, Neil Collinson² and the GiACTA Investigators, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Roche Products Ltd., Welwyn Garden City, United Kingdom, ³Genentech, South San Francisco, CA, ⁴Abteilung für Rheumatologie, Dresden, Germany, ⁵General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁶Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁸Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁹Friedrich-Alexander-University Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁰Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹¹Hospital for Special Surgery, Cornell, New York, NY
Background/Purpose: The efficacy and safety of tocilizumab (TCZ), an IL-6 receptor-alpha inhibitor, was evaluated in patients with giant cell arteritis (GCA) in GiACTA, a randomized,…
Abstract Number: 2373 • 2016 ACR/ARHP Annual Meeting
Patient Preference for Display of Electronic Patient-Reported Outcomes in Osteoarthritis Clinical Trials: Wording Emphasis, Question Format, and Navigation Button Placement
Laura Khurana¹, Ellen Durand¹, Sarah Gary¹, Tony Otero¹, Chris Hall¹, Aisling Ryan², Christopher J. Evans² and Susan Dallabrida¹, ¹ERT, Boston, MA, ²Endpoint Outcomes, Boston, MA
Background/Purpose: Electronic patient-reported outcomes (ePROs) are a reliable method for collecting patient data in osteoarthritis clinical trials and offer many advantages over paper collection; however,…

« Previous Page
1
…
5
6
7
8
9
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].